BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
BioAge Labs, Inc.NASDAQ: BIOA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $24.07M (cash outflow) rose 35.3% year over year, behind the +64.1% change in trailing-twelve-month free cash flow. Sequentially, it fell 15.1% from the prior quarter. Over 3 fiscal years it compounded at +31.4% a year.
Context
- Free cash flow amounted to 915.5% of revenue in FY2025.
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +35.3% toward the trailing-twelve-month pace of +64.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (82.35M) USD
- Year-over-year change
- -58.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (82.35M) | -58.7% |
| FY2024 | 2024-12-31 | (51.89M) | -38.3% |
| FY2023 | 2023-12-31 | (37.53M) | -3.4% |
| FY2022 | 2022-12-31 | (36.28M) | — |
Free Cash Flow vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +64.1% is the 2nd highest of 9, against a peer median of -9.6%.
- Free cash flow amounts to 859.1% of revenue for BIOA, versus a peer median of 22.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $147.86M USD | +17.2% | +2.4% | — | |
| LTM Mar 2026 | $143.28M USD | +47.4% | +39.4% | — | |
| LTM Mar 2026 | $141.09M USD | -34.5% | -3.0% | 364.6% | |
| LTM Mar 2026 | $109.53M USD | -44.7% | -12.8% | — | |
| LTM Mar 2026 | $102.38M USD | +1.6% | +13.6% | 5078.2% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $88.63M USD | +64.1% | +31.4% | 859.1% |
| LTM Mar 2026 | CA$76.88M CAD | -56.6% | -44.6% | 24.6% | |
| LTM Mar 2026 | CA$36.07M CAD | +1163.8% | -34.4% | 11.6% | |
| LTM Mar 2026 | $10.47M USD | — | -36.2% | 7.7% | |
| LTM Mar 2026 | $8.87M USD | -20.7% | -43.9% | 21.2% | |
| Peer median (excluding BIOA) | — | -9.6% | -12.8% | 22.9% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.